A Study of ARRY-382 in Combination With Pembrolizumab for the Treatment of Patients With Advanced Solid Tumors

NCT02880371 · clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
TERMINATED
Status
82
Enrollment
INDUSTRY
Sponsor class

Stopped Study was halted prematurely due to insufficient efficacy. Not due to safety reasons.

Conditions

Interventions

Sponsor

Pfizer